Compare KPTI & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KPTI | STXS |
|---|---|---|
| Founded | 2008 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.8M | 164.1M |
| IPO Year | 2013 | 2004 |
| Metric | KPTI | STXS |
|---|---|---|
| Price | $1.98 | $1.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | ★ $16.00 | $4.00 |
| AVG Volume (30 Days) | ★ 1.6M | 1.2M |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $146,067,000.00 | $29,346,617.00 |
| Revenue This Year | N/A | $28.22 |
| Revenue Next Year | $22.36 | $30.47 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 0.57 | N/A |
| 52 Week Low | $1.80 | $1.24 |
| 52 Week High | $10.99 | $3.59 |
| Indicator | KPTI | STXS |
|---|---|---|
| Relative Strength Index (RSI) | 14.97 | 35.40 |
| Support Level | N/A | N/A |
| Resistance Level | $6.96 | $1.97 |
| Average True Range (ATR) | 0.74 | 0.12 |
| MACD | -0.66 | -0.01 |
| Stochastic Oscillator | 2.42 | 14.84 |
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.